Amphastar Pharmaceuticals (AMPH) Competitors

Scholar Rock (NASDAQ:SRRK) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Does the media favor SRRK or AMPH?

In the previous week, Scholar Rock had 8 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 13 mentions for Scholar Rock and 5 mentions for Amphastar Pharmaceuticals. Scholar Rock's average media sentiment score of 0.92 beat Amphastar Pharmaceuticals' score of 0.66 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do institutionals and insiders believe in SRRK or AMPH?

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 13.3% of Scholar Rock shares are held by insiders. Comparatively, 27.5% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has more risk & volatility, SRRK or AMPH?

Scholar Rock has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Do analysts recommend SRRK or AMPH?

Scholar Rock presently has a consensus price target of $42.67, indicating a potential upside of 9.84%. Amphastar Pharmaceuticals has a consensus price target of $32.33, indicating a potential upside of 45.22%. Given Amphastar Pharmaceuticals' higher possible upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Amphastar Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Is SRRK or AMPH more profitable?

Amphastar Pharmaceuticals has a net margin of 19.38% compared to Scholar Rock's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 22.20% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-118.22%	-82.01%
Amphastar Pharmaceuticals	19.38%	22.20%	10.40%

Which has better earnings and valuation, SRRK or AMPH?

Amphastar Pharmaceuticals has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	$33.19M	111.13	-$246.29M	-$2.53	-15.35
Amphastar Pharmaceuticals	$730.66M	1.44	$159.52M	$2.76	8.07

Summary

Amphastar Pharmaceuticals beats Scholar Rock on 10 of the 17 factors compared between the two stocks.